ArticleBehavioural brain research2026
PET-measured tau deposition in emotion-related brain regions is differentially associated with depressive symptoms in individuals with versus without Alzheimer's disease pathology.
Article in Behavioural brain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Depressive symptoms are common in patients diagnosed with Alzheimer's Disease (AD) and can also precede AD as a risk factor and/or prodrome. Brain deposition of hyper-phosphorylated tau is a hallmark pathology of AD. Tau deposition in brain regions involved in emotional processing is likely to be pathophysiologically relevant to these links between AD and depression. We used 18F-MK6240 PET to measure tau in amygdala, hippocampus, and nucleus accumbens-regions implicated in depression-in 141 participants with and without AD. In addition to tau PET, participants underwent amyloid-beta (Aβ) PET, MRI, and cognitive evaluation. Depressive symptoms were assessed with the Beck Depression Inventory (BDI). Multiple regression analyzed contributions of tau and Aβ status (positive vs. negative), depression (BDI > 13), cognition (impaired vs. normal), age and sex to tau burden in the three regions. A significant interaction between tau status and depression prompted subgroup analyses of tau-positive (n = 34) and tau-negative (n = 107) participants. Among tau-positive participants, depression was associated with greater tau in the nucleus accumbens, a region critical for reward processing and motivation. This finding suggests that tau-mediated accumbens dysfunction may contribute to anhedonia, a key symptom of depression that is particularly common in AD-related depression. In tau-negative participants, greater depression was associated with less tau in the medial temporal lobe. This unexpected finding requires confirmation through further research, but could reflect impaired neurogenesis in depression without AD pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.